COMP <GO>
AARD vs NXTC // EV/EBITDA & P/E VALUATION
Aardvark Therapeutics Inc. (NASDAQ) VS. NextCure Inc. (NASDAQ) • 15-METRIC TALLY: AARD 1
— NXTC 1
■ METRIC PARITY
LAST: $1.44 (-4.64%) • MKT CAP: $31.5M
valuation
—
LAST: $6.53 (+2.92%) • MKT CAP: $29.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AARD VS. NXTC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AARD | NXTC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.9 | 54.3 | -29.41 | NXTC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $31.5M | $29.9M | $1.6M | AARD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AARD REV | NXTC REV | AARD GROSS % | NXTC GROSS % | AARD FCF | NXTC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$54.3M | -$49.6M |
| FY 2024 | $0 | $0 | — | — | -$18.2M | -$41.3M |
| FY 2023 | — | $0 | — | — | — | -$53.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AARD // BETA —
NXTC // BETA —